The roles of obesity and gender on the relationship between metabolic risk factors and non-alcoholic fatty liver disease in Koreans

2009 ◽  
Vol 25 (2) ◽  
pp. 150-155 ◽  
Author(s):  
Kayoung Lee ◽  
Jung-Ah Sung ◽  
Jun-Su Kim ◽  
Tae-Jin Park
Keyword(s):  
Risk Factors ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Metabolic Risk Factors ◽  
Metabolic Risk ◽  
Alcoholic Fatty Liver ◽  
And Gender ◽  
The Relationship ◽  
Alcoholic Fatty Liver Disease

scholarly journals Implementation of a care bundle improves the management of patients with non-alcoholic fatty liver disease

2021 ◽  
pp. flgastro-2020-101480
Author(s):  
Laura Jane Neilson ◽  
Louise Macdougall ◽  
Phey Shen Lee ◽  
Timothy Hardy ◽  
David Beaton ◽  
...  
Keyword(s):  
Risk Factors ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Metabolic Risk Factors ◽  
Care Bundle ◽  
Metabolic Risk ◽  
Lifestyle Advice ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

BackgroundNon-alcoholic fatty liver disease (NAFLD) is common and is associated with liver-related and cardiovascular-related morbidity. Our aims were: (1) to review the current management of patients with NAFLD attending hospital clinics in North East England (NEE) and assess the variability in care; (2) develop a NAFLD ‘care bundle’ to standardise care; (3) to assess the impact of implementation of the NAFLD care bundle.MethodsA retrospective review was conducted to determine baseline management of patients with NAFLD attending seven hospitals in NEE. A care bundle for the management of NAFLD was developed including important recommendations from international guidelines. Impact of implementation of the bundle was evaluated prospectively in a single centre.ResultsBaseline management was assessed in 147 patients attending gastroenterology, hepatology and a specialist NAFLD clinic. Overall, there was significant variability in the lifestyle advice given and management of metabolic risk factors, with patients attending an NAFLD clinic significantly more likely to achieve >10% body weight loss and have metabolic risk factors addressed. Following introduction of the NAFLD bundle 50 patients were evaluated. Use of the bundle was associated with significantly better documentation and implementation of most aspects of patient management including management of metabolic risk factors, documented lifestyle advice and provision of NAFLD-specific patient advice booklets.ConclusionThe introduction of an outpatient ‘care bundle’ led to significant improvements in the assessment and management of patients with NAFLD in the NEE and could help improve and standardise care if used more widely.

scholarly journals Evidence based literature review of clinical management of non-alcoholic fatty liver disease in real world settings

2017 ◽  
Vol 6 (5) ◽  
pp. 1020
Author(s):  
Gourdas Choudhuri ◽  
Varun Gupta
Keyword(s):  
Risk Factors ◽  
Liver Disease ◽  
Fatty Liver ◽  
Lifestyle Intervention ◽  
Real World ◽  
Fatty Liver Disease ◽  
Metabolic Risk Factors ◽  
Metabolic Risk ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

The aim of the present review is to understand the gap between real world clinical practices, guidelines recommendations and to propose minimum essentials that can be followed in clinical practice in NAFLD patients in India. A detailed literature search of published medical reports in English language was performed on electronic databases such as PubMed and Cochrane, from 2000 to 2016 using relevant search terms. The search yielded 25 relevant articles whose full texts were retrieved and evaluated. Non-alcoholic fatty liver disease (NAFLD) is an emerging cause of liver disease in India. It is observed that physicians under appreciate the overlap between NAFLD and metabolic risk factors, thus missing a significant proportion of high-risk NAFLD patients. Lifestyle intervention is generally considered the first line therapy for patients with NAFLD without steatohepatitis while pharmacotherapy (in addition to lifestyle intervention) is suggested for patients with non-alcoholic steatohepatitis (NASH). Current therapies are directed towards improving the metabolic parameters which contribute to disease pathogenesis. Pharmacological therapies for NAFLD and NASH include antioxidants such as vitamin E and ursodeoxycholic acid; insulin sensitizers such as metformin and thiazolidinones, weight loss drugs like orlistat and consideration of bariatric surgery for morbidly obese patients. High degree of suspicion is necessary for diagnosing NAFLD in patients with metabolic risk factors. Further studies are required from India as genotype/clinico-pathological profile of Indian NAFLD patients differ from the western population. Further, prospective studies will fill the various missing links associated with management of NAFLD in Indian patients in a more effective manner.

scholarly journals Comparative analysis of metabolic risk factors for progression of non-alcoholic fatty liver disease

2021 ◽  
Vol 7 (2) ◽  
pp. 241-247
Author(s):  
Vincent J. H. Yao ◽  
Michael Sun ◽  
Aivi A. Rahman ◽  
Zachariah Samuel ◽  
Joyce Chan ◽  
...  
Keyword(s):  
Risk Factors ◽  
Liver Disease ◽  
Comparative Analysis ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Metabolic Risk Factors ◽  
Metabolic Risk ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Comorbidity of non-alcoholic fatty liver disease and cardiovascular disease: focus on ademetionine and ursodeoxycholic acid

2021 ◽  
Vol 1 (29) ◽  
pp. 13-20
Author(s):  
O. A. Polyakova ◽  
O. D. Ostroumova ◽  
G. P. Kovaleva ◽  
E. E. Pavleeva
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
Liver Disease ◽  
Fatty Liver ◽  
Ursodeoxycholic Acid ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Medical Needs ◽  
The Relationship ◽  
Alcoholic Fatty Liver Disease

Changes in the nature of the interaction of risk factors and global aging of the population have led to a rapid increase in patients with combined pathology, elevated to the rank of a new non-infectious epidemic. The previously existing ‘one disease, one patient’ paradigm is losing its relevance and no longer meets medical needs, therefore patients with comorbidities need a broader approach and individualized treatment regimens, which are currently not fully defined. According to modern concepts, the coexistence of pathogenetically and pathophysiologically interrelated two or more diseases in one individual is defined by the term ‘comorbidity’. The most common comorbidity phenotype is cardiometabolic. Of particular interest is the relationship between cardiovascular disease (CVD) and non-alcoholic fatty liver disease (NAFLD), since both diseases are highly prevalent in the population and have common metabolic risk factors (obesity, diabetes mellitus, hypertension, and dyslipidemia). In addition, there is evidence that NAFLD is an independent risk factor for CVD, which suggests not only the presence of common pathogenetic mechanisms other than metabolic pathways, but also the likelihood that treatment of liver disease can reduce the burden of CVD. In this regard, this review comprehensively analyzes the relationship between NAFLD and CVD and discusses a possible therapeutic strategy, including the use of a combination of ademetionine with ursodeoxycholic acid.

Abstract P395: Non-Alcoholic Fatty Liver Disease in a Lean Population is Associated with Hypertension Independent of Metabolic Risk Factors

Circulation ◽  
2014 ◽  
Vol 129 (suppl_1) ◽  
Author(s):  
Adil Karim ◽  
Pragya Sinha ◽  
Ehimen Aneni ◽  
Ebenezer T Oni ◽  
Michael J Blaha ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Density Lipoprotein ◽  
Metabolic Risk Factors ◽  
Metabolic Risk ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver

Introduction: Hypertension is the most common causal risk factor for coronary artery disease. The increased prevalence of hypertension in those with nonalcoholic fatty liver disease (NAFLD) is well studied. Less well studied is the prevalence of hypertension in lean (BMI<25) individuals with NAFLD. This warrants attention since the burden of cardiovascular disease is increasingly shifting to the lean. Methods: The data for this study was obtained from a cohort of 6464 Brazilians (41.4+/-9 Y, 62% M) free of diabetes mellitus or cardiovascular disease. Of these, 39% (n=2508) were lean (BMI<25). Hypertension was defined as systolic BP (SBP) ≥ 140 mmHg or DBP ≥90 mmHg, self-identification as hypertensive or being on medication for hypertension. NAFLD was diagnosed using ultrasound in those with <20g/d alcohol intake. Results: The prevalence of hypertension in the lean population was nine percent. NAFLD was significantly associated with the presence of hypertension. The prevalence of hypertension was 16% and 8% in those with and without NAFLD respectively (p<0.001). In a multivariate analysis controlling for age, gender, triglyceride and high density lipoprotein cholesterol, the risk of hypertension in those with NAFLD was 1.54 times those without NAFLD(p<0.001). Conclusion: There is significantly increased prevalence of hypertension in lean, healthy individuals with NAFLD. This association is present even after adjusting for age, gender and metabolic risk factors. This relationship needs to be explored further since an increasing number of lean individuals have NAFLD on examination (Younossi et al., 2012).

Sign in / Sign up

Export Citation Format

Share Document